The inhibition of this process via blocking the importins was reported to suppress ELK1’s activation and was found to be the mechanism underlying carvedilol’s melanoma-preventive activity, thus underscoring how this notion could be expanded, and more research should be conducted in this direction. The gene discussed is ELK1; the disease is melanoma.